Psoriasis Aggravated by Adalimumab: A Paradoxical Adverse Reaction / 대한피부과학회지
Korean Journal of Dermatology
; : 513-516, 2010.
Article
em Ko
| WPRIM
| ID: wpr-73477
Biblioteca responsável:
WPRO
ABSTRACT
Adalimumab, a recombinant human IgG monoclonal antibody, selectively blocks tumor necrosis factor-alpha (TNF-alpha) and has been successfully used in the treatment of immune-mediated diseases. In particular, its efficacy has been proven in the treatment of rheumatoid arthritis, spondylarthritis, lymphoproliferative diseases and inflammatory bowel disease. Its use has also been studied for the treatment of psoriasis and yet, paradoxically, cases of new onset or exacerbation of psoriasis continue to increase in patients undergoing treatment with anti TNF-alpha agents. A 51-year-old woman had arthritis for a year and was diagnosed with psoriatic arthritis. After she had received adalimumab for psoriatic arthritis five times during one year, erythematous eruptions were found on her entire body. She then stopped adalimumab therapy for two months, although her skin lesions did not resolve. The patient was diagnosed with psoriasis through biopsy and began using cyclosporine, a topical steroid used for treatment of psoriasis.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Artrite
/
Artrite Reumatoide
/
Psoríase
/
Pele
/
Biópsia
/
Imunoglobulina G
/
Doenças Inflamatórias Intestinais
/
Artrite Psoriásica
/
Fator de Necrose Tumoral alfa
/
Ciclosporina
Limite:
Female
/
Humans
Idioma:
Ko
Revista:
Korean Journal of Dermatology
Ano de publicação:
2010
Tipo de documento:
Article